B
PBYI icon

Bailard’s Puma Biotechnology PBYI Stock Holding History

Bailard’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Hold
18,100
– – ﹤0.01% 748
2026
Q1 		$116K Buy
+18,100
New +$117K ﹤0.01% 721
2025
Q2 		– Sell
-24,702
Closed -$73.1K – 823
2025
Q1 		$73.1K Buy
+24,702
New +$77.3K ﹤0.01% 728
2023
Q2 		– Sell
-14,102
Closed -$43.6K – 760
2023
Q1 		$43.6K Sell
14,102
-39,398
-74% -$149K ﹤0.01% 699
2022
Q4 		$226K Hold
53,500
– – 0.01% 615
2022
Q3 		$127K Hold
53,500
– – 0.01% 623
2022
Q2 		$152K Buy
+53,500
New +$133K 0.01% 632

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bailard's PBYI Position: Q2 2026 in Review

Bailard held its Puma Biotechnology (PBYI) position steady in Q2 2026 at 18,100 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #748.

Bailard first reported a position in PBYI in Q2 2022 and has held it in 7 quarters since. The position peaked at $226K in Q4 2022. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Bailard held 18,100 shares of Puma Biotechnology worth $147K as of Q2 2026.
  • Bailard left its Puma Biotechnology share count unchanged in Q2 2026.
  • Puma Biotechnology made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #748 holding.
  • Bailard first reported a position in Puma Biotechnology in Q2 2022 and has held it in 7 quarters since.
  • Bailard's Puma Biotechnology position peaked at $226K in Q4 2022.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.